DOCSLIB.ORG

Pumps Or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pumps Or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes Diabetes Care Volume 41, December 2018 2471 Denice S. Feig,1,2,3 Rosa Corcoy,4,5 Pumps or Multiple Daily Injections Lois E. Donovan,6 Kellie E. Murphy,1,2,3 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL Jon F.R. Barrett,7 J. Johanna Sanchez,7 in Pregnancy Involving Type 1 Tim Wysocki,8 Katrina Ruedy,9 fi Craig Kollman,9 George Tomlinson,3,10 and Diabetes: A Prespeci ed Analysis Helen R. Murphy,11,12,13 on behalf of the of the CONCEPTT Randomized CONCEPTT Collaborative Group* Trial Diabetes Care 2018;41:2471–2479 | https://doi.org/10.2337/dc18-1437 OBJECTIVE 1Mount Sinai Hospital, Sinai Health System, To compare glycemic control, quality of life, and pregnancy outcomes of women Toronto, Ontario, Canada 2Lunenfeld-Tanenbaum Research Institute, Tor- using insulin pumps and multiple daily injection therapy (MDI) during the onto, Ontario, Canada Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy 3Department of Medicine, University of Toronto, Trial (CONCEPTT). Toronto, Ontario, Canada 4Hospital de la Santa Creu i Sant Pau, Barcelona, RESEARCH DESIGN AND METHODS Spain 5 fi CIBER-BBN, Zaragoza, Spain This was a prespeci ed analysis of CONCEPTT involving 248 pregnant women from 6University of Calgary, Calgary, Alberta, Canada 7 31 centers. Randomization was stratified for pump versus MDI and HbA1c. The Sunnybrook Research Institute, Toronto, On- primary outcome was change in HbA1c from randomization to 34 weeks’ gestation. tario, Canada 8 ’ Key secondary outcomes were continuous glucose monitoring (CGM) measures, Nemours Children s Health System, Jacksonville, FL maternal-infant health, and patient-reported outcomes. 9Jaeb Center for Health Research, Tampa, FL 10University Health Network, Toronto, Ontario, RESULTS Canada At baseline, pump users were more often in stable relationships (P = 0.003), more 11Cambridge University Hospitals NHS Founda- P P tion Trust, Cambridge, U.K. likely to take preconception vitamins ( = 0.03), and less likely to smoke ( = 0.02). 12 ’ fi 6 Department of Women and Children s Health, Pump and MDI users had comparable rst-trimester glycemia: HbA1c 6.84 0.71 vs. King’s College London, London, U.K. 6.95 6 0.58% (51 6 7.8 vs. 52 6 6.3 mmol/mol) (P = 0.31) and CGM time in target 13Department of Medicine, University of East (51 6 14 vs. 50 6 13%) (P = 0.40). At 34 weeks, MDI users had a greater decrease in Anglia, Norwich, U.K. HbA1c (20.55 6 0.59 vs. 20.32 6 0.65%, P = 0.001). At 24 and 34 weeks, MDI users Corresponding author: Denice S. Feig, d.feig@ utoronto.ca. were more likely to achieve target HbA1c (P = 0.009 and P = 0.001, respectively). Pump users had more hypertensive disorders (P = 0.011), mainly driven by increased Received 5 July 2018 and accepted 18 September 2018. gestational hypertension (14.4 vs. 5.2%; P = 0.025), and more neonatal hypogly- P This article contains Supplementary Data online cemia (31.8 vs. 19.1%, = 0.05) and neonatal intensive care unit (NICU) at http://care.diabetesjournals.org/lookup/suppl/ admissions >24 h (44.5 vs. 29.6%; P = 0.02). Pump users had a larger reduction doi:10.2337/dc18-1437/-/DC1. in hypoglycemia-related anxiety (P = 0.05) but greater decline in health/well-being *A complete list of the members of the CONCEPTT (P = 0.02). Collaborative Group can be found in the Sup- plementary Data online. CONCLUSIONS © 2018 by the American Diabetes Association. In CONCEPTT, MDI users were more likely to have better glycemic outcomes and less Readers may use this article as long as the work likely to have gestational hypertension, neonatal hypoglycemia, and NICU admis- is properly cited, the use is educational and not for profit, and the work is not altered. More infor- sions than pump users. These data suggest that implementation of insulin pump mation is available at http://www.diabetesjournals therapy is potentially suboptimal during pregnancy. .org/content/license. 2472 Pumps or Pens in Pregnancy Involving T1D? Diabetes Care Volume 41, December 2018 Insulin pumps or continuous subcutane- of blood glucose [SMBG]) compared with In the current analyses, the glycemic ous insulin infusions (CSIIs) are increas- SMBG alone. The results demonstrated control, quality of life, and pregnancy ingly used to optimize glucose control that use of CGM during pregnancy was outcomes of pregnant women using before and during pregnancy involving associated with improved glycemic con- pump therapy were compared with type 1 diabetes (T1D). Pump therapy trol with lower rates of neonatal com- those of pregnant women using MDI. has been shown to improve glycemic plications in both insulin pump and MDI The primary outcome was glycemic con- control, reduce severe hypoglycemic epi- users (17). trol as measured by a change in HbA1c sodes, and improve quality of life in The aim of this prespecified secondary from baseline to 34 weeks’ gestation. people with T1D outside of pregnancy (1). analysis was to compare maternal gly- Severe hypoglycemia was defined as However, the effectiveness of insulin cemic control, obstetric and neonatal an episode requiring third-party as- pump therapy during pregnancy is un- health outcomes, and patient-related sistance. Other secondary glycemic certain (2). Several randomized trials outcome measures in CONCEPTT partic- outcomes included CGM time in tar- showed no differences in glycemic con- ipants using pumps versus MDI. get range (63–140 mg/dL), time spent trol or pregnancy outcomes (3–6). These above and below the target range, studies were limited by small sample episodes of hypoglycemia (defined as sizes, performed in the 1980s using out- RESEARCH DESIGN AND METHODS CGM glucose values ,63 mg/dL for at dated equipment, and lacked statistical Full details of the clinical study protocol least 20 min), and glucose coefficient power for evaluating obstetric and neo- have previously been published (16). of variation (CV) to reflect glycemic natal outcomes. More recent cohort stud- Women with T1D were eligible if they variability. ies have found conflicting results, with were aged 18–40 years, had .12 months’ Patient-reported outcome measures some but not all finding differences in duration of diabetes, and were on an in- included the following questionnaires glycemic control (7–14). tensive insulin regimen using either a pump completed at baseline and 34 weeks’ The largest observational study, in- or multiple daily injections. Women plan- gestation. These assessed satisfaction cluding 113 pregnancies (.20 weeks’ ning pregnancy had to have an HbA1c level with their glucose monitoring system gestation), among insulin pump users between 7.0 and 10% (53–86 mmol/mol). (Blood Glucose Monitoring System Rat- reported clinically relevant differences Pregnant women had to have a live sin- ing Questionnaire) (18), fear of hypogly- fi in maternal HbA1c levels, favoring pump gleton fetus con rmed by ultrasound cemia (Hypoglycemia Fear Survey [HFS]-II]) users throughout pregnancy (10). De- before 14 weeks’ gestational age and an (19), diabetes-related distress (Prob- – spite lower HbA1c levels (0.7 and 0.3% HbA1c level between 6.5 and 10% (48 86 lem Areas in Diabetes scale) (20), and in the first and third trimesters, respec- mmol/mol). After a run-in period where qualityof life(12-ItemShort-FormSurvey tively), pregnancy outcomes were not eligible women wore a masked CGM for [SF-12]) (21). All questionnaires had ac- improved. Similar to an earlier Cochrane at least 96 h (neither they nor their clin- ceptable estimates of internal reliability review reporting higher birth weight in ical teams could see the glucose values), calculated using Cronbach’s a coefficient infants of mothers who used insulin women were randomized to the inter- or the Spearman-Brown split-half reliability pumps in pregnancy (15), this Canadian vention, where they received a CGM, coefficient. study also described a higher propor- or to the control group, where they Obstetric outcomes included hyper- tion of infants who were large for gesta- were instructed to continue with their tensive disorders (worsening chronic tional age (LGA): 55 vs. 39% for pump vs. usual SMBG at least seven times per hypertension, gestational hypertension multiple daily injection therapy (MDI). day. The CGM group were asked to with and without preeclampsia, and As with previous retrospective studies, perform a glucose test prior to insulin preeclampsia together and individu- these data were confounded by base- dose adjustment to verify the accuracy ally), cesarean section delivery, and line differences, with pump users being of the CGM, as required by the regula- gestational weight gain (22). Neonatal older, of higher parity, better educated, tory labeling instructions of the CGM outcomes included pregnancy loss (mis- and better prepared for pregnancy. How- manufacturer. carriage, stillbirth, neonatal death #28 ever, pump users also had a longer dura- In the main CONCEPTT trial, random- days of life), preterm birth (,37 and tion of diabetes and more retinopathy, ization was stratified by insulin delivery sys- ,34 weeks’ gestation), birth injury, suggesting that they may have had a tem (pump or MDI) and by baseline HbA1c shoulder dystocia, birth weight percen- more severe glycemic disturbance. level (,7.5 vs. $7.5% or 58 mmol/mol tile, rates of LGA or small for gestational The Continuous Glucose Monitoring in during pregnancy and ,8.0 vs. $8.0% or age (.90th or ,10th percentile us- Women With Type 1 Diabetes in Preg- 64 mmol/mol while planning pregnancy). ing Gestation Related Optimal Weight nancy Trial (CONCEPTT) was a multicen- Women in the SMBG planning pregnancy [GROW] software [23], which adjusts for ter, open-label, randomized trial in 325 and pregnant groups were asked to wear infant sex and gestational age, maternal women with T1D, who were either plan- another masked CGM at 12 and 24 weeks height, weight, parity, and ethnicity), ning pregnancy (n =110)orinearlypreg- and 24 and 34 weeks, respectively, for a neonatal hypoglycemia requiring intra- nancy (n = 215), from 31 centers in minimum of 96 h.
Load more

Recommended publications
  • 14. Management of Diabetes in Pregnancy: Standards of Medical
    Diabetes Care Volume 42, Supplement 1, January 2019 S165 14. Management of Diabetes in American Diabetes Association Pregnancy: Standards of Medical Care in Diabetesd2019 Diabetes Care 2019;42(Suppl. 1):S165–S172 | https://doi.org/10.2337/dc19-S014 14. MANAGEMENT OF DIABETES IN PREGNANCY The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. DIABETES IN PREGNANCY The prevalence of diabetes in pregnancy has been increasing in the U.S. The majority is gestational diabetes mellitus (GDM) with the remainder primarily preexisting type 1 diabetes and type 2 diabetes. The rise in GDM and type 2 diabetes in parallel with obesity both in the U.S. and worldwide is of particular concern. Both type 1 diabetes and type 2 diabetes in pregnancy confer significantly greater maternal and fetal risk than GDM, with some differences according to type of diabetes. In general, specific risks of uncontrolled diabetes in pregnancy include spontaneous abortion, fetal anomalies, preeclampsia, fetal demise, macrosomia, neonatal hypoglycemia, and neonatal hyperbilirubinemia, among others.
    [Show full text]
  • Neonatal Hypoglycemia in Diabetic Mothers: a Systematic Review Brook T
    Old Dominion University ODU Digital Commons Community & Environmental Health Faculty Community & Environmental Health Publications 2017 Neonatal Hypoglycemia in Diabetic Mothers: a Systematic Review Brook T. Alemu Old Dominion University Olaniyi Olayinka Old Dominion University, [email protected] Hind A. Baydoun Matthew oH ch Old Dominion University Muge Akpinar-Elci Old Dominion University, [email protected] Follow this and additional works at: https://digitalcommons.odu.edu/commhealth_fac_pubs Part of the Nutritional and Metabolic Diseases Commons Repository Citation Alemu, Brook T.; Olayinka, Olaniyi; Baydoun, Hind A.; Hoch, Matthew; and Akpinar-Elci, Muge, "Neonatal Hypoglycemia in Diabetic Mothers: a Systematic Review" (2017). Community & Environmental Health Faculty Publications. 25. https://digitalcommons.odu.edu/commhealth_fac_pubs/25 Original Publication Citation Alemu, B. T., Baydoun, H. A., Akpinar-Elci, M., Hoch, M., & Olayinka, O. (2017). Neonatal hypoglycemia in diabetic mothers: A systematic review. Current Pediatric Research, 21(1), 42-53. This Article is brought to you for free and open access by the Community & Environmental Health at ODU Digital Commons. It has been accepted for inclusion in Community & Environmental Health Faculty Publications by an authorized administrator of ODU Digital Commons. For more information, please contact [email protected]. Curr Pediatr Res 2017; 21 (1): 42-53 ISSN 0971-9032 www.currentpediatrics.com Neonatal hypoglycemia in diabetic mothers: A systematic review. Brook T Alemu1, Olaniyi Olayinka1, Hind A Baydoun2, Matthew Hoch1, Muge Akpinar Elci1 1Old Dominion University, College of Health Sciences, Norfolk, VA, USA. 2Department of Hospital Medicine, Johns Hopkins University School of Medicine, Baltimore, USA. Abstract Hypoglycemia occurs in approximately 8-30% of neonates born to mothers with diabetes.
    [Show full text]
  • Population-Based Study on Birth Outcomes Among Women
    www.nature.com/scientificreports OPEN Population‑based study on birth outcomes among women with hypertensive disorders of pregnancy and gestational diabetes mellitus Ya‑Wen Lin1,2, Ming‑Hung Lin3, Lee‑Wen Pai4, Jen‑Wei Fang5, Chih‑Hsin Mou6, Fung‑Chang Sung6,7,8,10 & Ya‑Ling Tzeng1,9,10* To evaluate birth outcomes in women with hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM), we used insurance data of Taiwan to evaluate 11 adverse neonatal outcomes of infants born to women with HDP (N = 7775) and with both HDP and GDM (HDP/GDM) (N = 1946), comparing to women with neither disorder (N = 19,442), matched by age. The impacts of preeclampsia/eclampsia were also evaluated. Results showed that Caesarean section delivery was near 1.7‑fold greater in the HDP/GDM and HDP groups than in comparisons. The preterm delivery rates were more than threefold greater in HDP/GDM group and HDP group than in comparisons with adjusted odds ratios (aORs) of 4.84 (95% confdence interval (CI) 4.34–5.40) and 3.92 (95% CI 3.65– 4.21), respectively, followed by jaundice (aORs 2.95 (95% CI 2.63–3.33) and 1.90 (95% CI 1.76–2.06)), and small gestation age (SGA) (aORs 6.57 (95% CI 5.56–7.75) and 5.81 (95% CI 5.15–6.55)). Incidence rates of birth trauma, patent ductus arteriosus, atrial septal defect, respiratory distress syndrome, and neonatal hypoglycemia were also higher in the HDP/GDM and HDP groups than in the comparison group.
    [Show full text]
  • Quantitative Assessment of the Effect of Pre-Gestational Diabetes and Risk of Adverse Maternal, Perinatal and Neonatal Outcomes
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 37), pp: 61048-61056 Research Paper Quantitative assessment of the effect of pre-gestational diabetes and risk of adverse maternal, perinatal and neonatal outcomes Lei Yu1,*, Xiao-Ling Zeng1,2,*, Ming-Liang Cheng3, Guo-Zhen Yang1, Bi Wang1,4, Zi-Wen Xiao1, Xin Luo2, Bao-Fang Zhang3, De-Wei Xiao4, Shuai Zhang5, Hua-Juan Liu3, Ya-Xin Hu3, Hou-Kang Lei1, Qin-Fen Li1 and Zheng-Rong Wang1 1Prenatal Diagnosis Center, Hospital Affiliated to Guizhou Medical University, Guiyang 550004, Guizhou, China 2The First Affiliated Hospital of Jinan University, Guangdong 510632, Guangzhou, China 3Department of Infectious Diseases, Hospital Affiliated to Guizhou Medical University, Guiyang 550004, Guizhou, China 4Department of Eugenics and Genetics, Guiyang Maternal and Child Health-Care Hospital, Guiyang 550003, Guizhou, China 5Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China *These authors have contributed equally to this work Correspondence to: Ming-Liang Cheng, email: [email protected] Guo-Zhen Yang, email: [email protected] Keywords: pre-gestational diabetes, adverse pregnancy outcomes, risk, meta-analysis Received: February 21, 2017 Accepted: April 05, 2017 Published: May 11, 2017 Copyright: Yu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Pregnancies complicated by pre-gestational diabetes (PGD) are associated with a higher rate of adverse outcomes, including an increased rage of preterm delivery, pregnancy-induced hypertension, pre-eclampsia, caesarean section, perinatal mortality, stillbirth, shoulder dystocia, macrosomia, small for gestational age, large for gestational age, low birth weight, neonatal hypoglycemia, neonatal death, low Apgar score, NICU admission, jaundice and respiratory distress.
    [Show full text]
  • Identifying Risk Effectors Involved in Neonatal Hypoglycemia Occurrence
    Bioscience Reports (2020) 40 BSR20192589 https://doi.org/10.1042/BSR20192589 Research Article Identifying risk effectors involved in neonatal hypoglycemia occurrence Tian Zhao*, Qiying Liu*, Man Zhou, Wei Dai, Yin Xu, Li Kuang, Yaqiong Ming and Guiyu Sun Department of Obstetrics, Guizhou Provincial People’s Hospital, Guizhou 550002, China Correspondence: Guiyu Sun ([email protected]) Hypoglycemia is a common metabolic condition in neonatal period, but severe and persis- tent hypoglycemia can cause neurological damage and brain injury. The aim of the present study was to analyze the risk factors of neonatal hypoglycemia in clinic. A total of 135 neona- tal hypoglycemia infants and 135 healthy infants were included in the present study. The differences in birth weight between neonatal hypoglycemia group and healthy control group were analyzed via t test. The associations between neonatal blood sugar level and relevant characteristic factors were explored using χ2 test. Binary logistic regression analysis was used to analyze risk factors related to the incidence of neonatal hypoglycemia. The results showed that the average birth weight was matched in neonatal hypoglycemia group and healthy control group. Neonatal blood sugar level of the infants was significantly associated with born term, birth weight, feed, gestational diabetes mellitus (GDM) and hypothermia (all P<0.05). Besides, logistic regression analysis showed that babies’ born term (odds ratio (OR) = 2.715, 95% confidence interval (95% CI): 1.311–5.625), birth weight (OR = 1.910, 95% CI: 1.234–2.955), improper feeding (OR = 3.165, 95% CI: 1.295–7.736) and mother’s GDM (OR = 2.184, 95% CI: 1.153–4.134) were high risk factors for neonatal hypoglycemia.
    [Show full text]
  • Materno-Fetal and Neonatal Complications of Diabetes
    Journal of Clinical Medicine Article Materno-Fetal and Neonatal Complications of y Diabetes in Pregnancy: A Retrospective Study Giampiero Capobianco 1,* , Alessandra Gulotta 1, Giulio Tupponi 1, Francesco Dessole 1, Maddalena Pola 1, Giuseppe Virdis 1, Marco Petrillo 1, Valerio Mais 2 , Giorgio Olzai 3, Roberto Antonucci 4, Laura Saderi 5 , Pier Luigi Cherchi 1, Salvatore Dessole 1 and Giovanni Sotgiu 5 1 Gynecologic and Obstetric Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy; [email protected] (A.G.); [email protected] (G.T.); [email protected] (F.D.); [email protected] (M.P.); [email protected] (G.V.); [email protected] (M.P.); [email protected] (P.L.C.); [email protected] (S.D.) 2 Gynecologic and Obstetric Clinic, University of Cagliari, 09121 Cagliari, Italy; [email protected] 3 Neonatal Intensive Care Unit (NICU), Sassari University, 07100 Sassari, Italy; [email protected] 4 Pediatric Clinic, Sassari University, 07100 Sassari, Italy; [email protected] 5 Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy; [email protected] (L.S.); [email protected] (G.S.) * Correspondence: [email protected]; Tel.: +39-3392-897-821; Fax: +39-079-228-265 Condensation: Retrospective study on materno-foetal and neonatal complications of diabetes in pregnancy. y Received: 5 July 2020; Accepted: 19 August 2020; Published: 21 August 2020 Abstract: The aim of this case–control study was to evaluate maternal–fetal and neonatal clinical outcomes in a group of patients with gestational diabetes mellitus (GDM) and pregestational diabetes such as diabetes mellitus type 1 (DM1) and diabetes mellitus type 2 (DM2) and compare them with those of patients without diabetes.
    [Show full text]
  • Glycemic Targets in the Second and Third Trimester of Pregnancy for Women with Type 1 Diabetes
    Page 1 of 30 Diabetes Care Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes Short title: Pregnancy glycemic targets in type 1 diabetes Authors: Michael J.A. Maresh, MD1, Valerie A. Holmes, PhD2, Christopher C. Patterson, PhD2, Ian S. Young, MD2, Donald W.M. Pearson, MD3, James D. Walker, MD4, David R. McCance, MD5; For the Diabetes and Pre-eclampsia Intervention Trial Study Group 1. Department of Obstetrics, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK 2. Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK 3. Department of Diabetes, Aberdeen Royal Infirmary, Aberdeen, UK; 4. Department of Diabetes, St John’s Hospital at Howden, West Lothian, UK 5. Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK Corresponding author:- Dr MJA Maresh, Department of Obstetrics, St Mary’s Hospital, Oxford Road, Manchester M13 9WL Tel: 0044 161 276 6426 Fax 0044 161 276 6426 Email : [email protected]. Word count: 3893 Tables: 4 Diabetes Care Publish Ahead of Print, published online November 3, 2014 Diabetes Care Page 2 of 30 Abstract Objective To assess the relationship between second and third trimester glycemic control and adverse outcomes in pregnant women with type 1 diabetes, as uncertainty exists about optimum glycemic targets. Research Design and Methods Pregnancy outcomes were assessed prospectively in 725 women with Type 1 diabetes from the Diabetes and Pre-eclampsia Intervention Trial. HbA1c (A1C) values at 26 and 34 weeks’ gestation were categorised into 5 groups; the lowest, <6.0% (42mmol/mol), being the reference.
    [Show full text]